Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Completed · Phase 3

Conditions studied: Kidney Neoplasms

In brief

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.

Key facts

Study ID

NCT00678392

Run by

Pfizer

People needed

723

Starts

2008-09-03

Expected to finish

2016-02-25

Last updated by the study team

2019-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed renal cell cancer with a component of clear cell subtype, with metastasis
• Evidence of measurable disease
• Must have failed one prior systemic first-line regimen for metastatic renal cell cancer

You may not qualify if…

• Prior treatment for metastatic renal cell cancer with more that one systemic first line therapy
• Major surgery less than 4 weeks or radiation less than 2 weeks of starting study drug

Where it is running

• Maurice Berkowtiz, MD — Burbank, California, United States
• Agajanian Institute of Oncology and Hematology — Downey, California, United States
• Los Angeles Hematology/Oncology Medical Group — Glendale, California, United States
• Los Angeles Hematology/Oncology Medical Group — Los Angeles, California, United States
• LAC-USC Medical Center — Los Angeles, California, United States
• USC Norris Cancer Hospital and Clinics — Los Angeles, California, United States
• Kenmar Research Institute — Los Angeles, California, United States
• Metropolitan Hematology/Oncology Medical Group — Los Angeles, California, United States
• Ronald Regan UCLA Medical Center — Los Angeles, California, United States
• UCLA — Los Angeles, California, United States
• Agajanian Institute of Oncology and Hematology — Montebello, California, United States
• Brian LeBerthon, MD, A Medical Corporation — West Covina, California, United States
• Agajanian Institute of Oncology and Hematology — Whittier, California, United States
• Rocky Mountain Cancer Centers — Aurora, Colorado, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• University of Colorado Denver: Division of Medical Oncology — Aurora, Colorado, United States
• Rocky Mountain Cancer Centers — Boulder, Colorado, United States
• Rocky Mountain Cancer Centers — Colorado Springs, Colorado, United States
• Rocky Mountain Cancer Centers, LLP — Denver, Colorado, United States
• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• Rocky Mountain Cancer Centers — Lakewood, Colorado, United States
• Rocky Mountain Cancer Centers — Littleton, Colorado, United States
• Rocky Mountain Cancer Centers — Lone Tree, Colorado, United States
• Rocky Mountain Cancer Centers — Longmont, Colorado, United States
• East Valley Hematology and Oncology Medical Group — Burbank, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.